Stockscreener 앱 받기
0.9922
0.54%
0.0053
시장 영업 전:
1.01
0.0178
+1.79%
전일 마감가:
$0.9869
열려 있는:
$1
하루 거래량:
259.02K
Relative Volume:
1.54
시가총액:
$30.90M
수익:
$22,000
순이익/손실:
$-61.44M
주가수익비율:
-0.3107
EPS:
-3.1938
순현금흐름:
$-43.64M
1주 성능:
+12.70%
1개월 성능:
-8.97%
6개월 성능:
-52.98%
1년 성능:
-68.99%
1일 변동 폭
$0.99
$1.02
1주일 범위
$0.8629
$1.02
52주 변동 폭
$0.7702
$3.8844
센티 바이오사이언시스 Stock (SNTI) Company Profile
명칭
Senti Biosciences Holdings Inc
전화
(650) 239-2030
주소
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Compare SNTI vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Holdings Inc
|
0.9922 | 30.74M | 22,000 | -61.44M | -43.64M | -3.1938 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
센티 바이오사이언시스 Stock (SNTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-14 | 개시 | H.C. Wainwright | Buy |
| 2025-06-06 | 개시 | Laidlaw | Buy |
| 2022-10-07 | 개시 | Morgan Stanley | Equal-Weight |
센티 바이오사이언시스 주식(SNTI)의 최신 뉴스
Senti Biosciences (SNTI) sells $10M notes, outlines up to $60M SENTI-202 CVR - Stock Titan
Senti Biosciences Stock Near $1: FDA Signal and Cash Test Put SNTI Back on Watch - Bez Kabli
Senti Biosciences Inc. Q1 2026 Earnings: Narrowing Losses and Gene Circuitry ProgressCFO Commentary Report - Newser
Senti Biosciences Holdings Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
SNTI Stock Price, Quote & Chart | SENTI BIOSCIENCES HOLDINGS I (NASDAQ:SNTI) - ChartMill
Senti Biosciences Holdings, Inc.Common Stock (NQ: SNTI - The Chronicle-Journal
Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure - TipRanks
SNTI Maintained by Chardan Capital -- Price Target Raised to $12 - GuruFocus
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program - Sahm
Senti Biosciences Secures FDA Support for SENTI-202 Donor Selection Strategy in AML - The Clinical Trial Vanguard
Senti Biosciences (NASDAQ: SNTI) flags going concern, lines up $40M convertible note financing - Stock Titan
Senti Biosciences Advances SENTI-202 to Pivotal Phase for AML, Secures $40M Financing, and Reports Reduced Q1 2026 Loss - Minichart
Senti Biosciences 1Q Loss $4.22M >SNTI - Moomoo
Senti Biosciences Advances SENTI-202 With New FDA Support - TipRanks
Senti Bio plans pivotal trial for AML therapy after FDA meeting - Investing.com
Senti Biosciences Holdings announces positive FDA RMAT meeting on registrational clinical and CMC strategy - marketscreener.com
Senti Bio plans pivotal trial for AML therapy after FDA meeting By Investing.com - Investing.com South Africa
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy - TradingView
Senti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid Leukemia - Quiver Quantitative
Senti Bio (NASDAQ: SNTI) wins FDA RMAT backing and lines up $40M funding - Stock Titan
Senti Biosciences 1Q Loss/Shr 14c >SNTI - Moomoo
SNTI Q1'26 Earnings: EPS estimate is (0.36) USD - TradingView
Number of shareholders of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
[15-12G] Senti Biosciences, Inc. SEC Filing - Stock Titan
Senti Biosciences Holdings, Inc.: Revenue and Earnings Analysts Forecasts Revisions | SNTI | US8169441024 - marketscreener.com
Why Senti Biosciences (SNTI) looks attractive at current levels (Breakout Watch) 2026-05-06RSI Overbought Stocks - newser.com
Celadon backs Senti Biosciences (SNTI) with $40M notes and majority stake - Stock Titan
Senti Biosciences Secures Convertible Note Financing with Celadon - TipRanks
Senti Biosciences Holdings (NASDAQ: SNTI) continues $17.5M ATM program - Stock Titan
Senti Biosciences Strikes Up to $40 Million Secured Convertible Notes Financing With Celadon - TradingView
Celadon-led $40M notes could give Senti (NASDAQ: SNTI) majority holder - Stock Titan
Senti Biosciences 2025 Executive Compensation, Officer Employment Arrangements, and Stock Awards Overview - Minichart
[EFFECT] Senti Biosciences, Inc. SEC Filing - Stock Titan
Senti Biosciences (NASDAQ: SNTI) files 10-K/A on 2025 pay, board and ownership - Stock Titan
Senti Biosciences Holdings, Inc.: Financial Data Forecasts Estimates and Expectations | SNTI | US8169441024 - marketscreener.com
Senti Biosciences completes holding company reorganization, stock continues on Nasdaq - Investing.com Australia
Senti Biosciences (NASDAQ: SNTI) adopts S-3 post-merger reorganization - Stock Titan
Senti Biosciences Holdings (SNTI) adopts S-3 after April 24, 2026 merger - Stock Titan
Senti Biosciences (NASDAQ: SNTI) deregisters 8.7M shares previously for resale - Stock Titan
SNTI Senti Biosciences Inc. shares rise nearly 14 percent even as Q4 2025 EPS misses Wall Street estimates. - Cổng thông tin điện tử tỉnh Tây Ninh
Senti Biosciences (SNTI) Stock: Why You Should Avoid It (Bullish Sentiment) 2026-04-20Aggressive Growth Stocks - Xã Vĩnh Công
Senti Biosciences (SNTI) Stock 52-Week Low (Rocket Higher) 2026-04-18Community Watchlist - Cổng thông tin điện tử tỉnh Lào Cai
Senti Biosciences Q4 Operating Income USD -18 - Moomoo
[SCHEDULE 13D/A] Senti Biosciences, Inc. Amended Major Shareholder Report - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Bioscie - The National Law Review
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 - Bitget
Cancer conference session will showcase Senti Bio's cell therapy approach - Stock Titan
SNTI: SENTI-202 achieved 50% ORR and 42% CR/CRh with excellent safety in R/R AML Phase 1 trial - TradingView
Is Senti Biosciences (SNTI) Stock Trading at Fair Value | Price at $0.87, Up 1.55%Reversal Signals - Newser
Growth Review: Will Senti Biosciences Inc outperform small cap indexes2026 Retail & AI Enhanced Execution Alerts - baoquankhu1.vn
SNTI Q4 2025 Earnings: Senti Biosciences Inc. misses EPS estimates, no Q4 revenue - newser.com
센티 바이오사이언시스 (SNTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):